Progress in pharmaceutical development presentation with improved pharmacokinetics: A new formulation for valproate

Acta Neurologica Scandinavica, Supplement

Volumn 112, Issue 182, 2005, Pages 26-32

  Genton, Pierre ^a  

^a CENTRE SAINT PAUL   (France)

Author keywords

Controlled release; Epilepsy; Pharmacokinetics; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMINE DERIVATIVE; CARBAMAZEPINE; CHRONOSPHERE; CLONAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; LAMOTRIGINE; MICROSPHERE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; SODIUM CHANNEL BLOCKING AGENT; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; DEPAKINE CHRONO;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED RELEASE FORMULATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; EPILEPSY; HUMAN; INFANTILE SPASM; LENNOX GASTAUT SYNDROME; MYOCLONUS EPILEPSY; PATIENT COMPLIANCE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION; ADOLESCENT; ADULT; AGE; AGED; CHEMISTRY; CHILD; DELAYED RELEASE FORMULATION; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; AGITATION; AREA UNDER THE CURVE; CONCENTRATION LOSS; DRUG ABSORPTION; DRUG SOLUTION; DRUG TOLERABILITY; FATIGUE; HEADACHE; MEMORY DISORDER; NERVOUSNESS; SIDE EFFECT; TABLET;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CHEMISTRY, PHARMACEUTICAL; CHILD; DELAYED-ACTION PREPARATIONS; EPILEPSY; FEMALE; HUMANS; MALE; MICROSPHERES; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; VALPROIC ACID;

EID: 29444460645     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2005.00524.x     Document Type: Conference Paper

References (31)

1. OLSEN RW. Phenobarbital and other barbiturates. Mechanism of action. In: LEVY RH, MATTSON RH, MELDRUM BS, PERUCCA E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002;491.
2. PELLOCK JM, PERHACH JL, SOFIA RD. Felbamate. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002;315.
3. BEN MENACHEM E. Vigabatrin. In: LEVY RH, MATTSON RH, MELDRUM BS, PERUCCA E, eds. Antiepileptic drugs, 5th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2002;858.
4. CHIRON C, DULAC O, BEAUMONT D et al. Therapeutic trial of vigabatrin in refractory infantile spasm. J Child Neurol 1991;6(Suppl. 2):S52-9.
5. AICARDI J, MUMFORD JP, DUMAS C, WOOD S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigators and Peer Review Groups. Epilepsia 1996;37:638-42.
6. GENTON P. When antiepileptic drugs aggravate epilepsy. Brain Dev 2000;22:75-80.
7. GENTON P, GELISSE P, THOMAS P, DRAVET C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000;55:1106-9.
8. GARNETT WR, LEVY B, MCLEAN AM et al. Pharmacokinetic evaluation of twice-daily extended-release carbamazepine (CBZ) and four-times-daily immediate-release CBZ in patients with epilepsy. Epilepsia 1998;39:274-9.
9. STEVENS RE, LIMSAKUN T, EVANS G, MASON DH JR. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). J Pharm Sci 1998;87:1531-4.
10. ROBERTS D, EASTER D, O_BRYAN-TEAR G. Epilim® Chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers. Biopharm Drug Dispos 1996;17:175-82.
11. RETZOW A, VENS-CAPELL B, WANGEMANN M. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation. Arzneimittelforschung 1997;47:1347-50.
12. CRAMER JA, MATTSON RH, PREVEY ML, SCHEYER RD, VALINDA L, OUELLETTE RN. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-7.
13. DOUGHTY J, BAKER GA, JACOBY A, LAVAUD V. Compliance and satisfaction with switching from an immediate-release to sustained-release formulation of valproate in people with epilepsy. Epilepsy Behav 2003;4:710-6.
14. PELLOCK JM. Extended-release formulations: simplifying strategies in the management of antiepileptic drug therapy. Epilepsy Behav 2004;5:301-7.
15. PERUCCA E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16:695-714.
16. LEVY RH, SHEN D, ABBOTT F, et al. Valproic acid: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson BS, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2002;780-800.
17. LÖSCHER W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669-94.
18. MACDONALD RL, KELLY KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(Suppl. 2):S2-12.
19. MARTÍN ED, POZO MA. Valproate reduced synaptic activity increase induced by 4-aminopyridine at the hippocampal CA3-CA1 synapse. Epilepsia 2004a;45:436-40.
20. HASSEL B, IVERSEN EG, GJERSTAD L, TAUBOLL E. Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate. J Neurochem 2001;77:1285-92.
21. MARTÍN ED, POZO MA. Valproate reduced excitatory postsynaptic currents in hippocampal CA1 pyramidal neurons. Neuropharmacology 2004b;46:555-61.
22. JOHANNESSEN CU. Mechanisms of action of valproate: a commentatory. Neurochem Int 2000;37:103-10.
23. IADAROLA MJ, GALE K. Dissociation between drug-induced increases in nerve terminal and non-nerve terminal pools of GABA in vivo. Eur J Pharmacol 1979;59, 125-9.
24. 14C]glucose into amino acids. Neurochem Res 1982;7:1089-109.
25. HARITON C, CIESIELSKY S, SIMLER S et al. Distribution of sodium valproate and GABA metabolism in CNS of the rat. Biopharm Drug Dispos 1984;5:409-14.
26. BALDINO F, GELLER HM. Effect of sodium valproate on hypothalamic neurons in vivo and in vitro. Brain Res 1981;219:231-7.
27. LÖSCHER W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989;501:198-203.
28. BARRE J, BERGER Y. Pharmacokinetics of a newly developed sustained-release form of sodium valproate. Proceedings of the Fourth International Symposium on Sodium Valproate and Epilepsy, London, 1989.
29. COVANIS A, JEAVONS PM. Once-daily sodium valproate in the treatment of epilepsy. Dev Med Child Neurol 1980;22:202-4.
30. DULAC O. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once or twice daily administration. Pharmacotherapy 2005;25:35-41.
31. MOTTE J. Acceptability and tolerability of a new microsphere formulation of sodium valproate (Depakine® Chronosphere®) in monotherapy or children with epilepsy. Epilepsia 2005;46(Suppl. 6):266.